Eli Lilly and (LLY) Stock Price & Analysis

LLY$1,417.72—
Drug Manufacturers - GeneralMega CapGrowth StockHigh Quality
Compare
Market cap$1.35TEnterprise value$1.38TRevenue (TTM)$86.46BMarket positionTop 1%

Score

56
Neutral
Value
17
Quality
82
Growth
68

AI Analysis

Snapshot

Eli Lilly and scores 56/100, but the multiple is asking a lot (P/E 45.9). Under the hood: P/E 45.9, plus revenue compounding ~32% annually over recent years.

Price History

Bullish (65+)Neutral (45–64)Bearish (<45)

Score Breakdown

Market percentile scores loading…

Value

17
PE Ratio (F)–
PEG Ratio–
Free Cashflow Yield %–
EV/EBITDA Ratio–
Discount vs All Time Peak–
Discount vs 1Y Peak–

Growth

68
Earnings Forecast–
Last 3M Earnings Growth %–
12M Revenue Growth %–
12M Earnings Growth %–
5 YR CAGR % Earnings–
Analyst Price Forecast–

Quality

82
FCF Margin %–
Net Debt / EBITDA–
Operating Margin %–
Operating Margin Growth %–
ROCE %–
Current Ratio–

Financial Summary

Eli Lilly and Company (LLY) last printed $1,417.72. Equity value is $1.35T. Trailing earnings multiple 48.86. The revenue row is reported history. Targets and ratings are on the forecast page.

Financials

2016201720182019202020212022202320242025
$21.22B$19.97B$21.49B$22.32B$24.54B$28.32B$28.54B$34.12B$45.04B$65.18B

About

Eli Lilly and Company is a prominent global pharmaceutical firm dedicated to the research, development, and commercialization of human medicines across the world. Its therapeutic offerings include a comprehensive suite of diabetes medications. This encompasses various insulin formulations like Basaglar, the Humalog family (e.g., Mix 75/25, U-100, U-200, Mix 50/50), insulin lispro products (including protamine and mix 75/25), and the Humulin line (e.g., 70/30, N, R, U-500). Furthermore, Eli Lilly provides specialized treatments for type 2 diabetes, such as Jardiance, Trajenta, and Trulicity. In oncology, Eli Lilly offers a robust portfolio targeting various cancers. These include Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza, indicated for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal and various head and neck cancers; Retevmo, used in metastatic NSCLC, medullary thyroid, and other thyroid cancers; Tyvyt for relapsed or refractory classic Hodgkin's lymphoma and non-squamous NSCLC; and Verzenio, prescribed for HR+, HER2- metastatic breast cancer, node-positive, and early breast cancer. For autoimmune and inflammatory conditions, the company markets Olumiant for rheumatoid arthritis, and Taltz, which addresses plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis. Addressing neurological and pain management needs, Eli Lilly provides Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain. Emgality is available for migraine prevention and episodic cluster headaches, while Zyprexa treats schizophrenia, bipolar I disorder, and aids in bipolar maintenance. Other significant products include Bamlanivimab and etesevimab, along with Bebtelovimab, both developed for COVID-19. Cialis is offered for erectile dysfunction and benign prostatic hyperplasia, and Forteo is available for osteoporosis. Eli Lilly actively engages in strategic collaborations with numerous partners, including Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Established in 1876, Eli Lilly and Company maintains its corporate headquarters in Indianapolis, Indiana.

Eli Lilly and (LLY) Stock Price & Analysis

LLY price $1,417.72 —

Ticker
LLY
Price
$1,417.72
Change
—
Market cap
$1.35T
P/E
48.86
Forward P/E
30.59
Dividend yield
0.47%
Beta
0.45
Sector
Healthcare
Industry
Drug Manufacturers - General
Stocklytics score
56
Value
17
Quality
82
Growth
68

Stocklytics score rationale: value 17, quality 82, growth 68.

AI Score 62. The score reflects strong reported profitability, with a net margin of 0.319, offset by elevated valuation multiples of 45.8899 P/E and 31.3949 price-to-book. Growth, estimates, and price-trend evidence were not provided, limiting confidence

Summary

Eli Lilly and Company operates in Healthcare within Drug Manufacturers - General. The company reports a net margin of 31.9% and a dividend yield of 0.5%.

Valuation

The stock trades at a P/E of 45.9 and a price-to-book ratio of 31.4. These multiples indicate a valuation that depends on sustained earnings strength.

Quality

A net margin of 31.9% indicates strong profitability based on the available facts. No balance-sheet, cash-flow, or return-on-capital figures are provided.

Growth

No revenue, earnings-growth, estimate-revision, or price-trend data are provided. Growth cannot be assessed from the supplied facts.

Risks

The P/E of 45.9 and price-to-book ratio of 31.4 create valuation risk if profitability or growth expectations weaken. The dividend yield of 0.5% provides limited income support.

Insights · Dividends · Forecast · Financials · Learn

Stocklytics home · Screener